Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007;22(5):311-7.
doi: 10.1007/s10654-007-9121-6. Epub 2007 May 5.

Association between tobacco smoke exposure and levels of C-reactive protein in the Oslo II Study

Affiliations

Association between tobacco smoke exposure and levels of C-reactive protein in the Oslo II Study

Christian Madsen et al. Eur J Epidemiol. 2007.

Abstract

It is well known that tobacco smoke exposure is related to the risk of developing cardiovascular diseases and events. One mechanism could be that tobacco smoke acts on the cardiovascular system by altering the autonomic function and/or inducing inflammatory responses. We used data from 3 744 men aged 67-77 years from the city of Oslo that participated in the health screening for the Oslo II Health Study in 2000, to explore associations between C-reactive protein and environmental exposures including exposure to tobacco smoke products. Levels of C-reactive protein were higher in current smokers (2.05 mg/l, IQR, 1.11-4.17 mg/l), compared to former-smokers (1.58 mg/l, IQR, 0.83-3.03 mg/l) and non-smokers (1.26 mg/l, IQR, 0.65-2.40 mg/l). The risk of elevated C-reactive protein increased with both numbers of current cigarettes smoked per day and numbers of pack-years of smoking, when other factors were adjusted for (P < 0.001). We found a positive dose-response relationship between amount of current cigarette smoking and elevated C-reactive protein levels. These findings support the idea that the induction or exacerbation of inflammation could be a mechanism by which smoking promotes atherosclerotic cardiovascular diseases.

PubMed Disclaimer

References

    1. Arterioscler Thromb Vasc Biol. 1997 Jun;17(6):1121-7 - PubMed
    1. Curr Opin Lipidol. 2002 Aug;13(4):383-9 - PubMed
    1. J Clin Invest. 1993 Apr;91(4):1351-7 - PubMed
    1. J Am Coll Cardiol. 1998 May;31(6):1226-33 - PubMed
    1. Circulation. 1999 Jul 20;100(3):230-5 - PubMed

Publication types